Phospho-KCNJ11 (T224) Antibody

What is KCNJ11 and why is phosphorylation at T224 significant?

KCNJ11 is an integral membrane protein that functions as an inward-rectifier type potassium channel. This protein exhibits a greater tendency to allow potassium to flow into cells rather than out and is controlled by G-proteins. KCNJ11 is typically found associated with the sulfonylurea receptor (SUR) . The phosphorylation at threonine 224 represents a critical post-translational modification that likely influences channel function, protein-protein interactions, and cellular signaling cascades.

Phosphorylation events are essential for activation of various cellular pathways, and site-specific phosphorylation at T224 may regulate KCNJ11's contribution to potassium homeostasis in different physiological contexts . Mutations in KCNJ11 are associated with several disorders including familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), non-insulin-dependent diabetes mellitus type II (NIDDM), transient neonatal diabetes mellitus type 3 (TNDM3), and permanent neonatal diabetes mellitus (PNDM) .

How does the Phospho-KCNJ11 (T224) antibody specifically detect the phosphorylated form?

The Phospho-KCNJ11 (T224) antibody is a rabbit polyclonal antibody raised against a synthetic phosphopeptide corresponding to residues surrounding T224 of human KCNJ11 . This antibody utilizes the principle of structural recognition to specifically detect KCNJ11 only when phosphorylated at threonine 224, allowing researchers to distinguish between phosphorylated and non-phosphorylated forms of the protein .

The specificity is achieved through a multi-stage production process that includes:

• Development using synthetic phosphopeptides conjugated with KLH (Keyhole Limpet Hemocyanin) as immunogens

• Extensive affinity purification using both positive and negative adsorption methodologies

• Validation through testing against non-phosphorylated peptides to ensure selective binding to the phosphorylated form

This selective recognition makes the antibody valuable for monitoring the activation state of KCNJ11 in various experimental systems.

What applications is the Phospho-KCNJ11 (T224) antibody validated for?

The Phospho-KCNJ11 (T224) antibody has been validated for the following applications with recommended dilutions:

The antibody has been specifically tested in Western blot analysis of untreated HeLa cell lysates and synthesized peptide-treated HeLa cell lysates, demonstrating its ability to detect endogenous levels of KCNJ11 only when phosphorylated at threonine 224 . While not explicitly validated for other applications, phosphospecific antibodies are generally used in a variety of immunodetection methods including immunohistochemistry and flow cytometry as demonstrated with other phosphospecific antibodies .

What are the optimal storage and handling conditions for this antibody?

To maintain the functional integrity of the Phospho-KCNJ11 (T224) antibody, researchers should adhere to the following storage and handling recommendations:

The antibody's performance may deteriorate with repeated freeze-thaw cycles, so it's crucial to create appropriate working aliquots upon receipt . This practice preserves the antibody's sensitivity and specificity for detecting phosphorylated KCNJ11.

What controls should be included when working with this antibody?

For rigorous experimental design with the Phospho-KCNJ11 (T224) antibody, researchers should implement the following controls:

• Positive control: Cell lysates known to contain phosphorylated KCNJ11 at T224, such as specific treated HeLa cell lysates

• Negative control:

  • Untreated cell lysates with minimal phosphorylation at T224

  • Samples treated with phosphatase to remove phosphate groups

• Peptide competition assay:

  • Incubation with the specific phosphopeptide used as immunogen should block signal

  • Non-phosphorylated peptide corresponding to the same region should not block signal

• Validation using genetic approaches:

  • Samples expressing site-directed mutants (T224A) where the phosphorylation site is abolished

  • KCNJ11 knockout or knockdown samples to confirm antibody specificity

These controls collectively ensure the observed signals are genuinely representing phosphorylation at T224 rather than non-specific binding or artifacts.

How can Phospho-KCNJ11 (T224) antibody be used to investigate diabetes pathophysiology?

The Phospho-KCNJ11 (T224) antibody represents a powerful tool for investigating diabetes pathophysiology given KCNJ11's established role in insulin secretion regulation and diabetes development. Research applications include:

• Correlation of T224 phosphorylation with beta-cell function: Examine how changes in KCNJ11 phosphorylation state at T224 relate to insulin secretion dynamics in pancreatic beta-cell models

• Epigenetic regulation studies: Recent research has shown that methylation patterns of KCNJ11 vary significantly by geography and ethnicity, with hypomethylation of specific CpG sites in the KCNJ11 promoter region observed in patients with type 2 diabetes mellitus (T2DM) . Researchers can investigate whether these epigenetic changes affect T224 phosphorylation levels.

• Mechanistic studies of KCNJ11 mutations: Using the antibody to analyze how disease-associated mutations in KCNJ11 (implicated in NIDDM, TNDM3, and PNDM) affect T224 phosphorylation status and subsequent channel function .

• Drug response evaluation: Monitoring phosphorylation changes at T224 in response to sulfonylureas and other diabetes medications to understand their mechanism of action at the molecular level.

• Pathway identification: Using phosphorylation status to elucidate upstream kinases and phosphatases that regulate KCNJ11 in normal and diabetic states.

These applications can provide crucial insights into KCNJ11's role in glucose homeostasis dysregulation and potential therapeutic interventions.

What are the best approaches for optimizing Western blot protocols with this antibody?

Optimizing Western blot protocols for Phospho-KCNJ11 (T224) antibody requires attention to several critical factors:

• Sample preparation:

  • Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Maintain samples at 4°C throughout processing

  • Consider using phospho-protein enrichment techniques for low-abundance targets

• Gel electrophoresis considerations:

  • KCNJ11 has a theoretical molecular weight of 40 kDa , so use appropriate percentage gels (10-12%)

  • Include molecular weight markers spanning 25-75 kDa range

• Transfer and blocking optimization:

  • Consider methanol concentration in transfer buffer (10-20%)

  • Test blocking agents systematically (BSA vs. milk - BSA often preferred for phospho-epitopes)

  • Try varying blocking time and temperature (1-3 hours at room temperature or overnight at 4°C)

• Antibody incubation:

  • Begin with middle-range dilution (1:1000) and adjust based on results

  • Test both overnight at 4°C and 2-3 hours at room temperature

  • Prepare antibody in fresh buffer for each experiment

• Detection system:

  • Enhanced chemiluminescence (ECL) systems are typically suitable

  • Consider longer exposure times if signal is weak

  • Explore fluorescent secondary antibodies for more quantitative analysis

Each step should be systematically optimized, changing one variable at a time while maintaining careful documentation of results.

How can researchers validate the specificity of this antibody in their experimental systems?

Validating the specificity of Phospho-KCNJ11 (T224) antibody in your particular experimental system requires a multi-faceted approach:

• Peptide competition assays: Pre-incubate the antibody with:

  • The specific phosphopeptide corresponding to T224

  • A non-phosphorylated version of the same peptide

  • Unrelated phosphopeptides containing pThr residues
    Only the specific phosphopeptide should block signal recognition

• Manipulation of phosphorylation status:

  • Treat samples with phosphatases to eliminate signal

  • Use stimuli known to induce or suppress KCNJ11 phosphorylation

  • Compare signal between basal and stimulated conditions

• Genetic approaches:

  • Generate point mutations at T224 (T224A) that prevent phosphorylation

  • Use CRISPR/Cas9 to knockout KCNJ11 to confirm signal absence

  • Employ siRNA knockdown to demonstrate reduced signal intensity

• Antibody comparison:

  • Compare results with alternative antibodies against total KCNJ11

  • Use mass spectrometry to confirm phosphorylation at T224

• Immunoprecipitation followed by Western blot: Perform IP with total KCNJ11 antibody followed by Western blot with the phospho-specific antibody (and vice versa)

These validation steps should be tailored to your specific biological system and experimental objectives.

What are the considerations for using this antibody in co-immunoprecipitation studies?

When employing Phospho-KCNJ11 (T224) antibody for co-immunoprecipitation (co-IP) studies, several specialized considerations should be addressed:

• Buffer optimization:

  • Include phosphatase inhibitors to preserve phosphorylation status

  • Test different detergent concentrations to balance solubilization with epitope preservation

  • Consider adding protease inhibitors and reducing agents to prevent protein degradation

• Antibody orientation strategy:

  • Direct approach: Use the phospho-antibody for pull-down to specifically capture the phosphorylated form

  • Reverse approach: Pull-down with antibodies against interaction partners, then blot with phospho-KCNJ11 antibody

  • Sequential approach: Pull-down with total KCNJ11 antibody, then analyze phosphorylation status

• Control experiments:

  • Include IgG controls from the same species as the antibody

  • Compare results between phosphorylated and non-phosphorylated states

  • Verify results with reciprocal co-IP when possible

• Binding conditions optimization:

  • Test various incubation times (2 hours to overnight)

  • Compare different temperatures (4°C vs. room temperature)

  • Optimize antibody-to-protein ratios

• Elution considerations:

  • Determine if competitive elution with phosphopeptides might be more effective than harsh elution buffers

  • Consider native elution conditions to preserve protein-protein interactions

The KCNJ11 (phospho T224) antibody has been validated through affinity chromatography , suggesting its potential utility in co-IP applications, though additional optimization may be required for specific experimental contexts.

How does phosphorylation at T224 potentially impact KCNJ11 channel function?

The phosphorylation of KCNJ11 at threonine 224 likely represents a critical regulatory mechanism with multifaceted functional implications:

• Channel gating modulation:

  • Phosphorylation may alter the conformational dynamics of the channel pore

  • T224 phosphorylation could influence the channel's sensitivity to ATP inhibition

  • The modification might affect the rectification properties of the inward-rectifier channel

• Protein-protein interaction regulation:

  • Phosphorylation could modulate KCNJ11's association with the sulfonylurea receptor (SUR)

  • T224 phosphorylation status might influence interactions with regulatory proteins and the cytoskeleton

  • Signaling complex formation may be phosphorylation-dependent

• Subcellular localization effects:

  • Phosphorylation may affect membrane trafficking and surface expression

  • The modification could influence channel clustering in specific membrane microdomains

  • Internalization and recycling rates might be regulated by T224 phosphorylation

• Pathophysiological implications:

  • Aberrant phosphorylation patterns could contribute to diabetes pathogenesis

  • The relationship between T224 phosphorylation and mutations causing neonatal diabetes or PHHI needs investigation

  • Correlations with epigenetic changes, such as the hypomethylation observed in T2DM patients, warrant further study

The precise functional consequences of T224 phosphorylation represent an important area for future research, particularly given KCNJ11's critical role in insulin secretion and glucose homeostasis.

Why might researchers observe weak or no signal when using this antibody?

Several methodological factors could contribute to weak or absent signals when working with Phospho-KCNJ11 (T224) antibody:

• Sample preparation issues:

  • Insufficient preservation of phosphorylation (inadequate phosphatase inhibitors)

  • Protein degradation during sample preparation

  • Low expression levels of KCNJ11 in the selected cell type

  • Ineffective cell lysis or protein extraction

• Technical limitations:

  • Suboptimal antibody dilution (recommended range: 1:500-1:3000 for Western blot, 1:100-1:500 for immunofluorescence)

  • Incompatible blocking agents (BSA typically preferred over milk for phospho-epitopes)

  • Inadequate primary or secondary antibody incubation times

  • Detection system sensitivity limitations

• Biological considerations:

  • Low basal phosphorylation state at T224 under the experimental conditions

  • Cell type-specific regulation of KCNJ11 phosphorylation

  • Treatments that might dephosphorylate KCNJ11 at T224

• Antibody handling issues:

  • Repeated freeze-thaw cycles reducing antibody activity

  • Improper storage conditions affecting antibody integrity

  • Antibody contamination or degradation

Systematic troubleshooting approaches include using positive controls (such as synthetic peptide-treated HeLa cell lysates) , testing different experimental conditions, and optimizing protein loading concentrations.

How can researchers address high background issues in immunofluorescence with this antibody?

High background in immunofluorescence experiments using Phospho-KCNJ11 (T224) antibody can be mitigated through several strategic approaches:

• Fixation optimization:

  • Compare paraformaldehyde versus methanol fixation methods

  • Test different fixation times and temperatures

  • Ensure complete permeabilization while minimizing structural damage

• Blocking enhancements:

  • Extend blocking time (1-3 hours)

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Consider dual blocking with both protein blockers and sera

• Antibody dilution adjustments:

  • Use more dilute antibody solutions (start at 1:500 and increase if needed)

  • Prepare antibodies in fresh blocking buffer for each experiment

  • Consider overnight incubation at 4°C with more dilute solutions

• Washing protocol refinements:

  • Increase number of washes (5-6 times rather than 3)

  • Extend washing duration (10-15 minutes per wash)

  • Add mild detergents (0.05-0.1% Tween-20) to washing buffers

• Controls and validation:

  • Include peptide competition controls to distinguish specific from non-specific binding

  • Test secondary antibody alone to identify potential sources of background

  • Compare with KCNJ11 knockout/knockdown samples

For HUVEC cells specifically, which have been validated with this antibody , optimizing cell density and ensuring healthy cultures can also significantly improve signal-to-noise ratio.

What could cause variability in Phospho-KCNJ11 (T224) detection between experimental replicates?

Variability in Phospho-KCNJ11 (T224) detection between replicates may stem from several sources that researchers should systematically address:

• Biological variability factors:

  • Cell cycle stage differences affecting phosphorylation levels

  • Variations in cell density and confluency between preparations

  • Subtle differences in culture conditions (media lot, serum batch, passage number)

  • Endogenous stimuli triggering signaling cascades that alter phosphorylation

• Sample processing inconsistencies:

  • Variable efficiency of phosphatase inhibitors

  • Differences in sample handling time before stabilization

  • Temperature variations during processing

  • Inconsistent protein extraction efficiency

• Technical variation sources:

  • Pipetting errors affecting antibody dilutions

  • Variations in transfer efficiency during Western blotting

  • Inconsistent blocking or washing procedures

  • Differences in detection reagent activity or exposure times

• Quantification challenges:

  • Variable background subtraction methods

  • Inconsistent region of interest selection for quantification

  • Different normalization approaches between experiments

  • Software settings variations in image analysis

To minimize variability, researchers should standardize protocols, process all comparative samples simultaneously, use internal standards, and employ robust statistical approaches for data analysis.

How should researchers interpret changes in KCNJ11 T224 phosphorylation in different physiological conditions?

Interpreting changes in KCNJ11 T224 phosphorylation requires a comprehensive analytical framework:

• Contextual interpretation strategies:

  • Always normalize phospho-signal to total KCNJ11 expression

  • Compare with established physiological modulators of KCNJ11 function

  • Interpret alongside functional measurements (e.g., potassium currents, insulin secretion)

  • Consider time-course dynamics rather than single time points

• Multi-level validation approaches:

  • Confirm phosphorylation changes using alternative techniques (mass spectrometry)

  • Correlate with known upstream kinase activities

  • Validate with genetic approaches (phospho-mimetic or phospho-resistant mutations)

  • Examine consequences on protein-protein interactions

• Physiological correlation matrix:

  • Map phosphorylation changes to glucose concentration variations

  • Examine correlation with insulin secretion dynamics

  • Assess relationship with membrane potential changes

  • Consider correlation with calcium signaling patterns

• Disease relevance framework:

  • Compare phosphorylation patterns in normal versus diabetic models

  • Examine in context of KCNJ11 mutations associated with diabetes

  • Consider the relationship with epigenetic changes, such as the hypomethylation of KCNJ11 promoter observed in T2DM patients

  • Evaluate therapeutic interventions' effects on phosphorylation status

This multifaceted approach ensures that phosphorylation data is interpreted within appropriate biological contexts and can be meaningfully translated to understanding KCNJ11's role in health and disease.

What are the considerations for quantifying relative phosphorylation levels of KCNJ11?

Accurate quantification of KCNJ11 phosphorylation levels demands methodological precision and appropriate analytical frameworks:

• Normalization strategies:

  • Always normalize phospho-signal to total KCNJ11 expression using parallel blots or sequential probing

  • Consider dual normalization to both total KCNJ11 and housekeeping proteins

  • Account for potential changes in total KCNJ11 expression under experimental conditions

  • Validate with loading controls appropriate for the subcellular fraction being analyzed

• Quantification methodologies:

  • Use densitometry with linear range validation

  • Consider fluorescent secondary antibodies for wider linear range

  • Perform multiple exposures to ensure signal is within quantifiable range

  • Use appropriate software with background subtraction capabilities

• Statistical approaches:

  • Run sufficient biological replicates (minimum n=3, preferably n≥5)

  • Apply appropriate statistical tests based on data distribution

  • Consider power analysis to determine sample size requirements

  • Report both absolute and relative changes with appropriate measures of variation

• Technical validation:

  • Include standard curves with known quantities of phosphorylated peptides

  • Use positive controls with established phosphorylation levels

  • Consider absolute quantification approaches using mass spectrometry

  • Verify antibody linearity across the concentration range being measured

These methodological considerations ensure that reported changes in KCNJ11 phosphorylation represent genuine biological phenomena rather than technical artifacts.

How should experiments be designed to investigate KCNJ11 phosphorylation in relation to insulin secretion?

Designing robust experiments to investigate the relationship between KCNJ11 T224 phosphorylation and insulin secretion requires a multifaceted approach:

• Model system selection:

  • Use physiologically relevant beta-cell lines (INS-1, MIN6, EndoC-βH1)

  • Consider primary islet preparations for higher physiological relevance

  • Develop appropriate transgenic models with phospho-mimetic or phospho-resistant KCNJ11

  • Evaluate human islet samples when available for translational relevance

• Experimental paradigm design:

  • Establish glucose dose-response relationships (2-20 mM glucose range)

  • Incorporate time-course analyses to capture dynamic phosphorylation changes

  • Include positive controls (sulfonylureas, GLP-1 agonists) and negative controls (diazoxide)

  • Design paired analyses of phosphorylation status and insulin secretion measurements

• Technical approach integration:

  • Combine Western blot analysis using Phospho-KCNJ11 (T224) antibody (1:500-1:3000)

  • Parallel immunofluorescence studies (1:100-1:500) to assess subcellular localization

  • Complement with electrophysiological measurements of KATP channel activity

  • Consider proteomics approaches for comprehensive phosphorylation profiling

• Mechanistic dissection strategies:

  • Use kinase inhibitors to identify regulatory pathways

  • Employ CRISPR/Cas9 to generate T224A (phospho-resistant) or T224E (phospho-mimetic) mutations

  • Investigate interplay with epigenetic regulation, given the observed hypomethylation of KCNJ11 promoter in T2DM

  • Examine relationship between phosphorylation and channel complex assembly with SUR subunits

This integrated experimental design provides a comprehensive framework for elucidating the functional significance of T224 phosphorylation in insulin secretion regulation.

What cell models are most appropriate for studying KCNJ11 T224 phosphorylation?

Selecting appropriate cell models for KCNJ11 T224 phosphorylation studies requires balancing physiological relevance with experimental tractability:

• Established beta-cell lines:

  • INS-1/INS-1E (rat): Express functional KATP channels and exhibit glucose-stimulated insulin secretion

  • MIN6 (mouse): Maintain many characteristics of primary beta-cells

  • EndoC-βH1 (human): Offer human relevance with stable phenotype

  • HIT-T15 (hamster): Historical model with well-characterized KATP channels

• Primary cell systems:

  • Isolated pancreatic islets: Highest physiological relevance but challenging for biochemical studies

  • Dispersed islet cells: Balance between native environment and experimental accessibility

  • Pseudoislets: Reconstituted from dissociated islet cells, restoring cell-cell contacts

• Non-beta cell models with known KCNJ11 expression:

  • HUVEC cells: Validated for this antibody in immunofluorescence studies

  • HeLa cells: Used in Western blot validation of this antibody

  • HEK293 cells expressing recombinant KCNJ11: Useful for mechanistic studies

• Model selection criteria matrix:

The selection should be guided by the specific research question, with consideration of native regulatory systems relevant to T224 phosphorylation.

How can Phospho-KCNJ11 (T224) antibody studies be integrated with functional assessments of potassium channels?

Integrating phosphorylation analysis with functional channel assessments provides crucial mechanistic insights through a multi-methodological approach:

• Electrophysiological correlations:

  • Patch-clamp recordings: Measure KATP channel activity in the same preparations analyzed for T224 phosphorylation

  • Design paradigm: Split samples for parallel phosphorylation and functional analyses

  • Time-resolution approach: Create temporal profiles of phosphorylation changes and channel activity

  • Pharmacological strategy: Use channel modulators and assess phosphorylation consequences

• Flux-based functional assessments:

  • Rubidium (⁸⁶Rb⁺) efflux assays: Quantify channel function in population of cells

  • Membrane potential dyes: Use fluorescent indicators (e.g., DiBAC₄(3)) to assess channel effects

  • Connect with phosphorylation: Process parallel samples for Western blot with Phospho-KCNJ11 (T224) antibody (1:500-1:3000)

• Integrated imaging approaches:

  • Combined immunofluorescence and functional imaging: Use Phospho-KCNJ11 (T224) antibody (1:100-1:500) with calcium indicators

  • FRET-based sensors: Develop reporters for real-time monitoring of T224 phosphorylation

  • Subcellular co-localization: Assess relationship between phosphorylation and channel distribution

• Molecular manipulation strategies:

  • Phospho-mutant expression: Compare T224A and T224E mutants functionally

  • Kinase/phosphatase modulation: Correlate enzyme activity with channel function

  • Structure-function analysis: Map phosphorylation effects to channel structural domains

This integrated approach connects molecular modifications with functional outcomes, essential for understanding how T224 phosphorylation regulates KCNJ11's physiological roles.

What considerations are important when designing time-course experiments for KCNJ11 phosphorylation?

Time-course experiments investigating KCNJ11 phosphorylation dynamics require careful consideration of temporal parameters and experimental variables:

• Temporal resolution planning:

  • Short-term kinetics: Include early time points (30 seconds, 1, 2, 5 minutes) to capture rapid phosphorylation events

  • Medium-term dynamics: Include intermediate points (15, 30, 60 minutes) for signaling cascade effects

  • Long-term regulation: Consider extended time points (2, 4, 8, 24 hours) for transcriptional and translational influences

  • Recovery phase: Include washout periods to assess reversibility of phosphorylation

• Methodological consistency considerations:

  • Synchronized stimulation: Ensure precise timing of treatments across samples

  • Rapid termination: Develop quick sample processing to "freeze" phosphorylation state

  • Parallel processing: Handle all time points identically to minimize technical variation

  • Internal controls: Include time-matched untreated controls for each time point

• Analytical approach planning:

  • Normalization strategy: Express phospho-KCNJ11 relative to total KCNJ11 at each time point

  • Curve-fitting approaches: Apply appropriate mathematical models to phosphorylation kinetics

  • Statistical analysis: Use repeated measures designs where appropriate

  • Data visualization: Develop clear graphical representations of temporal dynamics

• Biological context integration:

  • Pathway kinetics: Compare with known upstream kinase activation timelines

  • Functional correlation: Align with time-course of electrophysiological changes

  • Stimulus parameters: Consider concentration-dependent effects on phosphorylation kinetics

  • Cellular context: Account for potential desensitization or adaptation mechanisms

Proper execution of time-course experiments provides critical insights into the regulatory dynamics of KCNJ11 phosphorylation and its physiological significance.

How can experiments be designed to explore the relationship between KCNJ11 phosphorylation and diabetes pathogenesis?

Investigating the relationship between KCNJ11 T224 phosphorylation and diabetes pathogenesis requires a comprehensive experimental framework spanning multiple biological scales:

• Clinical sample analysis strategies:

  • Examine T224 phosphorylation in islets from diabetic versus non-diabetic donors

  • Correlate phosphorylation levels with clinical parameters (HbA1c, insulin secretion)

  • Compare phosphorylation patterns across diabetes subtypes (T1D, T2D, MODY)

  • Investigate relationship with KCNJ11 promoter methylation status, which has been shown to be hypomethylated in T2DM patients

• Animal model approaches:

  • Assess phosphorylation changes during diabetes progression in relevant models

  • Test intervention effects (diet, exercise, drugs) on phosphorylation status

  • Develop phospho-mutant animal models (T224A, T224E) to evaluate phenotypic consequences

  • Combine with metabolic phenotyping (glucose tolerance, insulin secretion)

• Mechanistic cellular studies:

  • Expose beta-cells to diabetogenic conditions (glucotoxicity, lipotoxicity, inflammation)

  • Monitor temporal changes in T224 phosphorylation using Western blot (1:500-1:3000)

  • Assess subcellular localization changes via immunofluorescence (1:100-1:500)

  • Connect phosphorylation to functional channel properties and insulin secretion

• Integrated multi-omics approaches:

  • Combine phosphoproteomics with transcriptomics and metabolomics

  • Map T224 phosphorylation to broader signaling networks

  • Identify diabetes-associated changes in kinases/phosphatases regulating T224

  • Develop predictive models connecting phosphorylation changes to disease progression

This multilevel experimental approach provides a comprehensive framework for understanding how alterations in KCNJ11 phosphorylation contribute to diabetes pathophysiology, potentially identifying novel therapeutic targets.